We also determined that nanocomplex (NC) delivery of a competitive peptide to block interaction of FUBP1 with PRMT5 is a potential therapeutic strategy to treat prostate cancer by preventing PRMT5-mediated FUBP1 methylation. The gene discussed is PRMT5; the disease is prostate cancer.